Current chemotherapeutic strategies for rhabdomyosarcoma

Expert Review of Anticancer Therapy

Volumn 5, Issue 2, 2005, Pages 283-294

  Ferrari, Andrea ^a   Casanova, Michela ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Chemotherapy; New drugs; Pediatric soft tissue sarcoma; Rhabdomyosarcoma; Risk stratification; Treatment protocols

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOXORUBICIN; ETOPOSIDE; IDARUBICIN; IFOSFAMIDE; IRINOTECAN; MELPHALAN; MESNA; NAVELBINE; TOPOTECAN; TROFOSFAMIDE; VINCA ALKALOID; VINCRISTINE; VINDESINE;

ANTINEOPLASTIC ACTIVITY; BONE MARROW TOXICITY; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CHEMOSENSITIVITY; CHILD; CHILDHOOD CANCER; CLINICAL TRIAL; COST BENEFIT ANALYSIS; DRUG BIOAVAILABILITY; DRUG MEGADOSE; FUTUROLOGY; GONAD DYSFUNCTION; HEMORRHAGIC CYSTITIS; HUMAN; LOW DRUG DOSE; META ANALYSIS; NEPHROTOXICITY; PRACTICE GUIDELINE; REVIEW; RHABDOMYOSARCOMA; SYSTEMATIC REVIEW;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CLINICAL TRIALS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; NEOPLASM STAGING; PROGNOSIS; RHABDOMYOSARCOMA; RISK ASSESSMENT;

EID: 17544367893     PISSN: 14737140     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737140.5.2.283     Document Type: Review

References (86)

1. Pappo AS, Shapiro DN, Crist WM, Maurer HM. Biology and therapy of pediatric rhabdomyosarcoma. J. Clin. Oncol. 13, 2123-2139 (1995).
2. Ries LAG, Smith MA, Gurney JG et al. Cancer incidence and survival among children and adolescents: United States SEER Program 1975-1999. National Cancer Institute, MD, USA, NIH Publication No. 99-4649 (1999).
3. Gurney JG, Young JL Jr, Roffers SD et al. Soft tissue sarcomas. In: Cancer Incidence and Survival among Children and Adolescents: United States SEER Program 1975-1999. National Cancer Institute, MD, USA, NIH Publication No. 99-4649 (1999).
4. Newton WA, Gehan EA, Webber BL et al. Classification of rhabdomyosarcomas and related sarcomas. Pathologic aspects and proposal for a new classification - an Intergroup Rhabdomyosarcoma Study. Cancer 70, 1073-1085 (1995).
5. Meyer WH, Spunt SL. Soft tissue sarcoma of childhood. Cancer Treat. Rev. 30, 269-280 (2004).
6. Ruymann FB, Grovas AC. Progress in the diagnosis and treatment of rhabdomyosarcoma and related soft tissue sarcomas. Cancer Invest. 18(3), 223-241 (2000).
7. Raney RB, Anderson JR, Barr FG et al. Rhabdomyosarcoma and undifferentiated sarcoma in first two decades of life: a selective review of Intergroup Rhabdomyosarcoma Study Group experience and rationale for Intergroup Rhabdomyosarcoma Study V. J. Pediatr. Hematol. Oncol. 23(4), 215-220 (2001).
8. Stevens M. Rhabdomyosarcoma. In: Evidence-based Paediatric Oncology. Pinkerton R, Philip T, Fervers B (Eds), BMJ Books, London, UK, 3-27 (2002).
9. Maurer HM, Beltangady M, Gehan EA et al. The Intergroup Rhabdomyosarcoma Study-I. A final report. Cancer 61, 209-220 (1988).
10. Maurer HM, Gehan EA, Beltangady M et al. The Intergroup Rhabdomyosarcoma Study-II. Cancer 71, 1904-1922 (1993).
11. Crist WM, Garnsey L, Beltangady MS et al. Prognosis in children with rhabdomyosarcoma: a report of the Intergroup Rhabdomyosarcoma Studies I and II. J. Clin. Oncol. 8, 443-452 (1990).
12. Crist WM, Gehan EA, Ragab AH et al. The third Intergroup Rhabdomyosarcoma Study. J. Clin. Oncol. 13, 610-630 (1995).
13. Crist WM, Anderson JR, Meza JL et al. Intergroup Rhabdomyosarcoma Study-IV: results for patients with nonmetastatic disease. J. Clin. Oncol. 19, 3091-3102 (2001).
14. Flamant F, Rodary C, Rey A et al. Treatment of non-metastatic rhabdomyosarocmas in childhood and adolescence. Result of the second study of the International Society of Paediatric Oncology: MMT84. Eur. J. Cancer. 34(7), 1050-1062 (1998).
15. Stewart RJ, Martelli H, Oberlin O et al. Treatment of children with nonmetastatic paratesticular rhabdomyosarcoma: results of the Malignant Mesenchymal Tumors studies (MMT 84 and MMT 89) of the International Society of Pediatric Oncology. J. Clin. Oncol. 19, 793-798 (2003).
16. Koscielniak E, Jurgens H, Winkler K et al. Treatment of soft tissue sarcoma in childhood and adolescence: a report of the German Co-operative Soft Tissue Sarcoma Study. Cancer 70(10), 2557-2567 (1992).
17. Koscielniak E, Harms D, Henze G et al. Results of treatment for soft tissue sarcoma in childhood and adolscence: a final report of the German Co-operative Soft Tissue Sarcoma Study CWS-86.J. Clin. Oncol. 17, 3706-3719 (1999).
18. Koscielniak E, Morgan M, Treuner J. Soft tissue sarcoma in children: prognosis and management. Paediatr. Drugs 4(1), 21-28 (2002).
19. Carli M, Pastore G, Perilongo G et al. Tumour response and toxicity after single high-dose versus standard five-day divided-dose dactinomycin in childhood rhabdomyosarcoma. J. Clin. Oncol. 6, 654-658 (1988).
20. Ferrari A, Bisogno G, Casanova C et al. Paratesticular rhabdomyosarcoma: report from the Italian and German Co-operative Group. J. Clin. Oncol. 20, 449-455 (2002).
21. Carli M, Passone E, Perilongo G, Bisogno G. Ifosfamide in pediatric solid tumors. Oncology 65(Suppl 2), 99-104 (2003).
22. Harmer MH. TNM Classification of Pediatric Tumors. UICC International Union Against Cancer, Geneva, Switzerland, 23-28 (1982).
23. Breneman JC, Lyden E, Pappo AS et al. Prognostic factors and clinical outcomes in children and adolescents with metastatic rhabdomyosarcoma - a report from the Intergroup Rhabdomyosarcoma Study IV. J. Clin. Oncol. 21(1), 78-84 (2003).
24. Treuner J, Suder J, Keim M et al. The predictive value of initial cytostatic response in primary unresectable rhabdomyosarcoma. Acta Oncol. 28, 67-72 (1989).
25. Breitfeld PP, Anderson J, Kao S et al. Assessment of response to induction therapy and its influence on 5-year failure-free survival (FFS) in Group III rhabdomyosarcoma (RMS): Intergroup Rhabdomyosarcoma Study (IRS)-IV experience. Proc. Am. Soc. Clin. Oncol. 23 (2004) (Abstract 8513).
26. Wharam MD, Meza J, Anderson J et al. Failure pattern and factors predictive of local failure in rhabdomyosarcoma: a report of group III patients on the Third Intergroup Rhabdomyosarcoma Study. J. Clin. Oncol. 22(10), 1902-1908 (2004).
27. Sung L, Anderson JR, Donaldson SS et al. Late events occurring five years or more after successful therapy in childhood rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. Eur. J. Cancer 40(12), 1878-1885 (2004).
28. Raney RB, Anderson JR, Kollath J et al. Late effects of therapy in 94 patients with localized rhabdomyosarcoma of the orbit: report from the Intergroup Rhabdomyosarcoma Study (IRS)-III, 1984-1991. Med. Pediatr. Oncol. 34(6), 413-420 (2000).
29. Paulino AC, Simon JH, Zhen W, Wen BC. Long-term effects in children treated with radiotherapy for head and neck rhabdomyosarcoma. Int. J. Radiat. Oncol. Phys. 48(5), 1489-1495 (2000).
30. Arndt C, Rodeberg D, Breitfeld PP et al. Does bladder preservation (as a surgical principle) lead to retain bladder function in bladder/prostate rhabdomyosarcoma? Report from the Intergroup Rhabdomyosarcoma Study IV. J. Urol. 17, 2396-2403 (2004).
31. Schuck A, Mattke AC, Schmidt B et al. Group II rhabdomyosarcoma and rhabdomyosarcomalike tumors: is radiotherapy necessary? J. Clin. Oncol. 22(1), 143-149 (2004).
32. Wolden SL, Anderson JR, Crist VM et al. Indications for radiotherapy and chemotherapy after complete resection in rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Studies I to III. J. Clin. Oncol. 17, 3468-3475 (1999).
33. Viswanathan AK, Grier HE, Litman HJ et al. Outcome for childen with group III rhabdomyosarcoma treated with or without radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 58(4), 1208-1214 (2004).
34. Oberlin O, Rey A, Anderson J et al. Treatment of orbital rhabdomyosarcoma: survival and late effects of treatment - results of an international workshop. J. Clin. Oncol. 19(1), 197-204 (2001).
35. Ruymann FB. The development of VAC chemotherapy in rhabdomyosarcoma: what does one do for an encore? Curr. Oncol. Rep. 5, 505-509 (2003).
36. Pappo AS, Etcubanas E, Santana VM et al. A Phase II trial of ifosfamide in previously untreated children and adolescents with unresectable rhabdomyosarcoma. Cancer 71(6), 2119-2125 (1993).
37. Stevens M, Flamant F. Ifosfamide for children with solid tumours. Lancet 335, 1398-1400 (1990).
38. Treuner J, Koscielniak E, Keim M. Comparison of the rates of response to ifosfamide and cyclophosphamide in primary unresectable rhabdomyosarcomas. Cancer Chemother. Pharmacol. 24(Suppl.), S48-S50 (1989).
39. Skinner R, Cotterill SJ, Stevens MC. Risk factors for nephrotoxicity after ifosfamide treatment in children: a UKCCSG Late Effects Group study. United Kingdom Children's Cancer Study Group. Br. J. Cancer 82(10), 1636-1645 (2000).
40. Lee BS, Lee JH, Kang HG et al. Ifosfamide nephrotoxicity in pediatric cancer patients. Pediatr. Nephrol. 16(10), 796-799 (2001).
41. Ruymann FB, Vietti T, Gehan E et al. Cyclophoshamide dose escalation in combination with vincristine and actinomycin-D (VAC) in gross residual sarcoma. J. Pediatr. Hematol. Oncol. 17, 331-337 (1995).
42. Baker KS, Anderson JR, Link MP et al. Benefit of intensified therapy for patients with local or regional embryonal rhabdomyosarcoma: results from the Intergroup Rhabdomyosarcoma Study IV. J. Clin. Oncol. 18(12), 2427-2434 (2000).
43. Spunt SL, Smith LM, Ruymann FB et al. Cyclophoshamide dose intensification during induction therapy for intermediate-risk pediatric rhabdomyosarcoma is feasible but does not improve outcome: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. Clin. Cancer Res. 10, 6072-6079 (2004).
44. Sandler E, Lyden E, Ruymann F et al. Efficacy of ifosfamide and doxorubicin given as a Phase II 'window' in children with newly diagnosed metastatic rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Study Group. Med. Pediatr. Oncol. 37, 442-448 (2001).
45. Stevens MC, Rey A, Bouvet N et al. SIOP MMT 95: intensified (6 drug) versus standard (IVA) chemotherapy for high risk non-metastatic rhabdomyosarcoma (RMS). Proc. Am. Soc. Clin. Oncol. 23 (2004) (Abstract 8515).
46. Treuner J, Brecht IB, Mattke AD et al. Interims report of the CWS-96-study: results of the treatment for soft tissue sarcomas in childhood. Med. Pediatr. Oncol. 41(4) (2003) (Abstract O-084).
47. Smith MA, Ungerleider RS, Horowitz ME, Simon R. Influence of doxorubicin dose intensity on response and outcome for patients with osteogenic sarcoma and Ewing's sarcoma. J. Natl Cancer Inst. 83, 1460-1470 (1991).
48. Bisogno G, Ferrari A, Bergeron C et al. The IVADo regimen, a pilot study with ifosfamide, vincristine, actinomycin and doxorubicin in children with metastatic soft tissue sarcoma. A pilot study by the European pediatric Soft Tissue Sarcoma Study Group. Cancer (2005) (In Press).
49. Breitfeld PP, Lyden E, Raney RB et al. Ifosfamide and etoposide are superior to vincristine and melphalan for pediatric metastatic rhabdomyosarcoma when administered with irradiation and combination chemotherapy: a report from the Intergroup Rhabdomyosarcoma Study. J. Pediatr. Hematol. Oncol. 23(4), 225-233 (2001).
50. Miser JS, Kinsella TJ, Triche TJ et al. Ifosfamide with Mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults. J. Clin. Oncol 5(8), 1191-1198 (1987).
51. Horowitz ME, Etcubanas E, Christensen ML et al. Phase II testing of melphalan in children with newly diagnosed rhabdomyosarcoma: a model for anticancer drug development. J. Clin. Oncol. 6 (2), 308-314 (1988).
52. Smith MA, Anderson B. Phase II window studies: 10 years of experience and counting. J. Pediatr. Hematol. Oncol. 23(6), 334-337 (2001).
53. Blaney SM, Needle MN, Gillespie et al. Phase II trial of topotecan administered as a 72-hour continuous infusion in children with refractory solid tumors: a collaborative Pediatric Branch, National Cancer Institute, and Children's Cancer Group study. Clin. Cancer Res. 4, 357-360 (1998).
54. Nitschke R, Parkurst J, Sullivan J et al. Topotecan in pediatric patients with recurrent and progressive solid tumors: a Pediatric Oncology Group Phase II study. J. Pediatr. Hematol. Oncol. 20, 315-318 (1998).
55. Pappo AS, Lyden E, Breneman J et al. Up-front window trial of topotecan in previously untreated children and adolescents with metastatic rhabdomyosarcoma: an Intergroup Rhabdomyosarcoma Study. J. Clin. Oncol. 19(1), 213-219 (2001).
56. Saylors RL, Stine KC, Sullivan J et al. Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group Phase II study. J. Clin. Oncol. 19(15), 3463-3369 (2001).
57. Walterhouse DO, Lyden ER, Breitfeld PP et al. Efficacy of topotecan and cyclophosphamide given as a Phase II window in children with newly diagnosed metastatic rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. J. Clin. Oncol. 22(8), 1-7 (2004).
58. Cosetti M, Wexler LH, Calleja E et al. Irinotecan for pediatric solid tumors: the Memorial Sloan-Kettering experience. J. Pediatr. Hematol. Oncol. 24(2), 84-85 (2002).
59. Vassal G, Doz F, Frappaz D et al. A Phase I study of irinotecan as a 3-week schedule in children with refractory or recurrent solid tumors. J. Clin. Oncol. 21(20), 3844-3852 (2003).
60. Pappo AS, Lyden E, Breitfeld PP et al. Irinotecan (CPT-11) is active against pediatric rhabdomyosarcoma (RMS): a Phase II window trial from the Soft Tissue Sarcoma Committee (STS) of the Children's Oncology Group (COG). Proc. Am. Soc. Clin. Oncol. 21 (2002) (Abstract 1570).
61. Carli M, Colombatti R, Oberlin O et al. High-dose melphalan with autologous stem-cell rescue in metastatic rhabdomyosarcoma. J. Clin. Oncol. 17(9), 2796-2802 (1999).
62. Koscielniak E, Klingebiel TH, Peters C et al. Do patients with metastatic and recurrent rhabdomysarcoma benefit from high-dose therapy with hematopoietic rescue? Report of the German/Austrian Pediatric Bone Marrow Transplantation Group. Bone Marrow Transplant 19(3), 227-231 (1997).
63. Boulad F, Kernan NA, LaQuaglia MP et al. High-dose induction chemotherapy followed by autologous bone marrow transplantation as consolidation therapy in rhabdomyosarcoma, extraosseus Ewing's sarcoma and undifferentiated sarcoma. J. Clin. Oncol. 16, 1697-1706 (1998).
64. Weigel BJ, Breitfeld PP, Hawkins D et al. Role of high-dose chemotherapy with hematopoietic stem cell rescue in the treatment of metastatic and recurrent rhabdomyosarcoma. J. Pediatr. Hematol. Oncol. 23(5), 272-276 (2001).
65. Mackall CL, Heiman LJ. High-dose chemotherapy for rhabdomyosarcoma: where do we go from here. J. Pediatr. Hematol. Oncol. 23(5), 266-267 (2001).
66. Meyers PA. High-dose therapy with autologous stem cell rescue for pediatric sarcomas. Curr. Opin. Oncol. 16, 120-125 (2004).
67. Womer RB, Daller RT, Fenton JG, Miser JS. Granulocyte colony stimulating factor permits dose intensification by interval compression in the treatment of Ewing's sarcoma and soft tissue sarcomas in children. Eur. J. Cancer 36(1), 87-94 (2000).
68. Kamen BA, Rubin E, Aisner J, Glatstein E. High-time chemotherapy or high time for low dose. J. Clin. Oncol. 18, 2935-2937 (2000).
69. Hanahan D, Bergers G, Bergsland E. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J. Clin. Invest. 105, 1045-1047 (2000).
70. Kerbel RS, Klement G, Pritchard KI, Kamen B. Continuos low-dose anti-angiogenic/metronomic chemotherapy: from the research laboratory into the oncology clinic. Ann. Oncol. 13, 12-15 (2002).
71. Klingebiel T, Koscielniak E, Beske F et al. High dose therapy versus oral maintenance: results of HD CWS 96 study for treatment of patients with metastasized soft tissue sarcoma. Med. Pediatr. Oncol. 41(4) (2003) (Abstract O-085).
72. Bertolini F, Paul S, Mancuso P et al. Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitors cells. Cancer Res. 63, 4342-4346 (2003).
73. Hayot C, Farinelle S, De Decker R et al. In vitro pharmacological characterizations of the anti-angiogenic and antitumor cell migration properties mediated by microtubule-affecting drugs, with special emphasis on the organization of the actin cytoskeleton. Int. J. Oncol. 21, 417-425 (2002).
74. Kusnher BH, Kramer K, Cheung NKV. Oral etoposide for refractory and relapsed neuroblastoma. J. Clin. Oncol. 17, 3221-3225 (1999).
75. Browder T, Butterfield CE, Kraling BM et al. Anti-angiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res. 60, 1878-1886 (2000).
76. Casanova M, Ferrari A, Spreafico F et al. Vinorelbine in previously treated advanced childhood sarcomas. Evidence of activity in rhabdomyosarcoma. Cancer 94(12), 3263-3268 (2002).
77. Epelman S, Aguiar S, Melaragno R et al. High response rate of vinorelbine in children and adolescents with refractory or recurrent rhabdomyosarcomas or other sarcomas. Med. Pediatr. Oncol. 33(3) (1999) (Abstract P-147).
78. Hill SA, Lonergan SJ, Denekamp J, Chaplin DJ. Vinca alkaloids: antivascular effects in a murine tumour. Eur. J. Cancer 29A, 1320-1324 (1993).
79. Klement G, Baruchel S, Rak J et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J. Clin. Invest. 105, R15-R24 (2000).
80. Nasti G, Errante D, Talamini R et al. Vinorelbine is an effective and safe drug for AIDS-related Kaposi's sarcoma: results of a Phase II study. J. Clin. Oncol. 18, 1550-1557 (2000).
81. Casanova M, Ferrari A, Bisogno G et al. Vinorelbine and low-dose cyclophosphamide in the treatment of pediatric sarcomas. Pilot study for the upcoming European Rhabdomyosarcoma Protocol. Cancer 101(7), 1664-1671 (2004).
82. Hawkins WG, Hoos A, Antonescu CR et al. Clinicopathologic analysis of patients with adult rhabdomyosarcoma. Cancer 91, 794-803 (2001).
83. Ferrari A, Dileo P, Casanova M et al. Rhabdomyosarcoma in adults: a retrospective analysis of 171 patients treated at a single institution. Cancer 98, 571-580 (2003).
84. Ablett S, Doz F, Morland B, Vassal G. European collaboration in trials of new agents for children with cancer. Eur. J. Cancer 40(12), 1886-1892 (2004).
85. Houghton PJ, Adamson PC, Blaney S et al. Testing of new agents in childhood cancer preclinical models: meeting summary. Clin. Cancer Res. 8, 3646-3657 (2002).
86. Houghton PJ, Horton JK, Houghton JA. Drug sensitivity and resistance in the xenograft model. In: Rhabdomyosarcoma and Related Tumors in Children and Adolescents. Maurer HM, Ruymann FB, Pochedly C (Eds). CRC Press, FL, USA, 187-203 (1991).